Search
AstraZeneca Acquires Modella AI to Accelerate Oncology Drug Development
2026-01-14 /
Read about 0 minute
Author：小编
According to a statement on January 13, AstraZeneca has acquired the biomedical artificial intelligence company Modella AI. The two parties will deepen their cooperation to promote the application of multimodal AI foundational models and AI agents across AstraZeneca's global oncology product portfolio. After the acquisition, Modella AI's generative and agent AI platform will be integrated into AstraZeneca's oncology drug development system, accelerating the clinical development process.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
